Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antirheumatic Agents | 24 | 2023 | 1294 | 4.760 |
Why?
|
Arthritis, Rheumatoid | 28 | 2023 | 3615 | 3.790 |
Why?
|
Drugs, Generic | 6 | 2020 | 409 | 2.960 |
Why?
|
Drug Prescriptions | 15 | 2021 | 1624 | 2.330 |
Why?
|
Medicare | 26 | 2023 | 6252 | 2.150 |
Why?
|
Angiotensin Receptor Antagonists | 6 | 2023 | 878 | 2.150 |
Why?
|
Heart Failure | 14 | 2023 | 10381 | 2.020 |
Why?
|
Cohort Studies | 65 | 2023 | 39918 | 1.660 |
Why?
|
Analgesics, Opioid | 16 | 2022 | 3545 | 1.640 |
Why?
|
Insurance Claim Review | 7 | 2021 | 739 | 1.460 |
Why?
|
Pregnancy Complications | 18 | 2022 | 2824 | 1.380 |
Why?
|
Drug Utilization | 5 | 2020 | 1182 | 1.370 |
Why?
|
Biological Products | 9 | 2022 | 816 | 1.360 |
Why?
|
Gout | 6 | 2023 | 554 | 1.360 |
Why?
|
Propensity Score | 17 | 2021 | 1755 | 1.350 |
Why?
|
Stroke Volume | 7 | 2023 | 4752 | 1.280 |
Why?
|
United States | 79 | 2023 | 68403 | 1.270 |
Why?
|
Renal Dialysis | 4 | 2021 | 1740 | 1.240 |
Why?
|
Medicaid | 16 | 2022 | 2656 | 1.230 |
Why?
|
Arthritis, Psoriatic | 6 | 2022 | 213 | 1.210 |
Why?
|
Allopurinol | 4 | 2021 | 192 | 1.190 |
Why?
|
Tumor Necrosis Factor-alpha | 8 | 2022 | 4409 | 1.160 |
Why?
|
Medication Errors | 4 | 2013 | 790 | 1.140 |
Why?
|
Databases, Factual | 18 | 2022 | 7683 | 1.130 |
Why?
|
Venous Thromboembolism | 5 | 2021 | 1592 | 1.080 |
Why?
|
Nursing Homes | 4 | 2013 | 988 | 1.060 |
Why?
|
Piperidines | 4 | 2022 | 1565 | 1.010 |
Why?
|
Abnormalities, Drug-Induced | 8 | 2021 | 321 | 0.970 |
Why?
|
Immunologic Factors | 4 | 2022 | 1543 | 0.940 |
Why?
|
Cardiovascular Diseases | 16 | 2023 | 14701 | 0.930 |
Why?
|
Gout Suppressants | 3 | 2021 | 164 | 0.890 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 984 | 0.880 |
Why?
|
Insurance, Health | 4 | 2019 | 2475 | 0.860 |
Why?
|
Neprilysin | 2 | 2022 | 426 | 0.850 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2023 | 2103 | 0.840 |
Why?
|
Research Design | 6 | 2023 | 5930 | 0.830 |
Why?
|
Pregnancy Trimester, First | 10 | 2021 | 836 | 0.800 |
Why?
|
Neonatal Abstinence Syndrome | 3 | 2022 | 108 | 0.800 |
Why?
|
Patient Preference | 2 | 2019 | 878 | 0.790 |
Why?
|
Gastrointestinal Agents | 4 | 2022 | 492 | 0.790 |
Why?
|
Biphenyl Compounds | 4 | 2023 | 884 | 0.790 |
Why?
|
Pyrimidines | 4 | 2022 | 2893 | 0.780 |
Why?
|
Electronic Health Records | 10 | 2023 | 4305 | 0.760 |
Why?
|
Drug Recalls | 1 | 2020 | 17 | 0.740 |
Why?
|
Heart Failure, Systolic | 1 | 2021 | 120 | 0.730 |
Why?
|
Hyperkalemia | 1 | 2022 | 208 | 0.730 |
Why?
|
Tetrazoles | 4 | 2023 | 804 | 0.730 |
Why?
|
Drug Utilization Review | 2 | 2018 | 246 | 0.720 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2020 | 335 | 0.710 |
Why?
|
Aged | 56 | 2023 | 161486 | 0.700 |
Why?
|
Polypharmacy | 1 | 2021 | 283 | 0.700 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 42 | 0.700 |
Why?
|
Humans | 141 | 2023 | 725187 | 0.700 |
Why?
|
Colitis, Ulcerative | 5 | 2022 | 1854 | 0.700 |
Why?
|
Drug Substitution | 2 | 2021 | 275 | 0.700 |
Why?
|
Osteoarthritis, Knee | 2 | 2019 | 1141 | 0.690 |
Why?
|
Anticoagulants | 7 | 2021 | 4425 | 0.690 |
Why?
|
Drug Labeling | 1 | 2021 | 233 | 0.670 |
Why?
|
Opioid-Related Disorders | 9 | 2022 | 1992 | 0.670 |
Why?
|
Calcium Phosphates | 1 | 2019 | 171 | 0.650 |
Why?
|
Spondylitis, Ankylosing | 2 | 2016 | 147 | 0.650 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 2954 | 0.640 |
Why?
|
Immunosuppressive Agents | 5 | 2021 | 4105 | 0.630 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2023 | 486 | 0.630 |
Why?
|
Chelating Agents | 1 | 2019 | 382 | 0.630 |
Why?
|
Alendronate | 2 | 2021 | 169 | 0.620 |
Why?
|
Female | 93 | 2023 | 375449 | 0.620 |
Why?
|
Prospective Payment System | 1 | 2018 | 134 | 0.610 |
Why?
|
Osteoporotic Fractures | 2 | 2021 | 383 | 0.610 |
Why?
|
Kidney Failure, Chronic | 2 | 2021 | 2517 | 0.610 |
Why?
|
Bone Density Conservation Agents | 3 | 2021 | 767 | 0.610 |
Why?
|
Rheumatic Diseases | 2 | 2020 | 556 | 0.590 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 3172 | 0.590 |
Why?
|
Pyrroles | 2 | 2022 | 1142 | 0.570 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 4827 | 0.560 |
Why?
|
Comparative Effectiveness Research | 3 | 2018 | 688 | 0.560 |
Why?
|
Marketing | 1 | 2018 | 205 | 0.560 |
Why?
|
Psoriasis | 5 | 2022 | 896 | 0.550 |
Why?
|
Medicare Part D | 1 | 2020 | 319 | 0.550 |
Why?
|
Diabetic Nephropathies | 1 | 2023 | 967 | 0.540 |
Why?
|
Drug Approval | 2 | 2018 | 735 | 0.530 |
Why?
|
Male | 68 | 2023 | 347096 | 0.530 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2018 | 3012 | 0.530 |
Why?
|
Congenital Abnormalities | 2 | 2017 | 689 | 0.530 |
Why?
|
Epidemiologic Research Design | 1 | 2018 | 369 | 0.520 |
Why?
|
Private Sector | 1 | 2018 | 390 | 0.520 |
Why?
|
Osteoarthritis, Hip | 1 | 2019 | 400 | 0.510 |
Why?
|
Hydroxychloroquine | 7 | 2022 | 400 | 0.510 |
Why?
|
Treatment Outcome | 23 | 2023 | 61761 | 0.510 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2274 | 0.510 |
Why?
|
Data Mining | 2 | 2023 | 550 | 0.510 |
Why?
|
Crohn Disease | 3 | 2022 | 2260 | 0.500 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2022 | 1403 | 0.500 |
Why?
|
Rheumatology | 2 | 2018 | 559 | 0.500 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2017 | 357 | 0.500 |
Why?
|
Epidemiologic Methods | 2 | 2017 | 1381 | 0.490 |
Why?
|
Warfarin | 2 | 2020 | 1481 | 0.490 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 454 | 0.490 |
Why?
|
Computer Simulation | 6 | 2019 | 6163 | 0.480 |
Why?
|
Immune System Diseases | 1 | 2016 | 259 | 0.480 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2022 | 2354 | 0.470 |
Why?
|
Diphosphonates | 1 | 2018 | 617 | 0.470 |
Why?
|
Uric Acid | 2 | 2023 | 756 | 0.460 |
Why?
|
Hip Fractures | 2 | 2018 | 919 | 0.460 |
Why?
|
Drug Combinations | 3 | 2023 | 1924 | 0.460 |
Why?
|
Medication Adherence | 3 | 2020 | 2015 | 0.460 |
Why?
|
Methadone | 1 | 2015 | 291 | 0.450 |
Why?
|
Osteoporosis | 2 | 2021 | 1566 | 0.440 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1404 | 0.440 |
Why?
|
Bone Marrow Transplantation | 1 | 2020 | 2768 | 0.430 |
Why?
|
Inflammatory Bowel Diseases | 4 | 2022 | 2331 | 0.430 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2023 | 11413 | 0.430 |
Why?
|
Pregnancy | 29 | 2022 | 28145 | 0.430 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12329 | 0.430 |
Why?
|
North Carolina | 4 | 2013 | 306 | 0.420 |
Why?
|
Osteoarthritis | 1 | 2019 | 1007 | 0.420 |
Why?
|
Risk Assessment | 15 | 2023 | 23185 | 0.420 |
Why?
|
Incidence | 14 | 2021 | 20750 | 0.420 |
Why?
|
Diabetes Mellitus | 3 | 2018 | 5522 | 0.410 |
Why?
|
Anticonvulsants | 6 | 2019 | 1865 | 0.400 |
Why?
|
Middle Aged | 45 | 2022 | 212292 | 0.400 |
Why?
|
Aged, 80 and over | 18 | 2022 | 57656 | 0.390 |
Why?
|
Morphine | 1 | 2015 | 648 | 0.390 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 1997 | 0.380 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1876 | 0.370 |
Why?
|
Pulmonary Embolism | 2 | 2021 | 2352 | 0.370 |
Why?
|
Drug Therapy, Combination | 5 | 2023 | 6460 | 0.370 |
Why?
|
Hyperlipidemias | 1 | 2015 | 785 | 0.370 |
Why?
|
Social Class | 1 | 2019 | 1955 | 0.370 |
Why?
|
Adult | 52 | 2022 | 211615 | 0.360 |
Why?
|
Probenecid | 2 | 2021 | 76 | 0.360 |
Why?
|
Venous Thrombosis | 1 | 2019 | 1217 | 0.360 |
Why?
|
Logistic Models | 8 | 2020 | 13358 | 0.360 |
Why?
|
Valine | 1 | 2011 | 416 | 0.360 |
Why?
|
Losartan | 1 | 2011 | 286 | 0.350 |
Why?
|
Hospital Mortality | 2 | 2020 | 5226 | 0.350 |
Why?
|
Glucocorticoids | 2 | 2022 | 2085 | 0.350 |
Why?
|
Sulfasalazine | 2 | 2021 | 80 | 0.340 |
Why?
|
Analgesics | 2 | 2013 | 1052 | 0.340 |
Why?
|
Risk Factors | 24 | 2023 | 71009 | 0.330 |
Why?
|
Hospitalization | 10 | 2023 | 9964 | 0.330 |
Why?
|
Administration, Oral | 3 | 2021 | 3909 | 0.320 |
Why?
|
Stroke | 6 | 2023 | 9579 | 0.310 |
Why?
|
Methotrexate | 5 | 2022 | 1711 | 0.310 |
Why?
|
Joint Diseases | 1 | 2011 | 472 | 0.310 |
Why?
|
Follow-Up Studies | 10 | 2020 | 38748 | 0.300 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1829 | 0.300 |
Why?
|
Lithium Compounds | 2 | 2019 | 216 | 0.290 |
Why?
|
Steroids | 1 | 2011 | 887 | 0.290 |
Why?
|
Health Care Costs | 1 | 2020 | 3174 | 0.290 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2021 | 385 | 0.290 |
Why?
|
Antipsychotic Agents | 5 | 2018 | 3012 | 0.280 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3496 | 0.280 |
Why?
|
Benzimidazoles | 1 | 2011 | 851 | 0.280 |
Why?
|
Pain | 3 | 2017 | 4830 | 0.280 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15442 | 0.270 |
Why?
|
Vitamin D | 2 | 2022 | 3177 | 0.270 |
Why?
|
Registries | 4 | 2018 | 7898 | 0.270 |
Why?
|
Risk | 11 | 2021 | 9700 | 0.260 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2069 | 0.260 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2010 | 0.260 |
Why?
|
Mortality | 3 | 2021 | 2827 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 9588 | 0.260 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7254 | 0.260 |
Why?
|
Alzheimer Disease | 2 | 2022 | 7561 | 0.260 |
Why?
|
Data Interpretation, Statistical | 3 | 2019 | 2728 | 0.250 |
Why?
|
Hemorrhage | 4 | 2023 | 3354 | 0.250 |
Why?
|
Young Adult | 21 | 2022 | 55781 | 0.250 |
Why?
|
Hypertension | 6 | 2019 | 8262 | 0.250 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 3056 | 0.240 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2075 | 0.240 |
Why?
|
Cleft Palate | 2 | 2018 | 517 | 0.230 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1479 | 0.230 |
Why?
|
Heart Failure, Diastolic | 1 | 2023 | 63 | 0.220 |
Why?
|
Case-Control Studies | 4 | 2021 | 21591 | 0.220 |
Why?
|
Comorbidity | 5 | 2020 | 10247 | 0.220 |
Why?
|
Prescription Drugs | 2 | 2021 | 578 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2022 | 10971 | 0.220 |
Why?
|
Adolescent | 16 | 2022 | 84401 | 0.220 |
Why?
|
Kidney | 1 | 2018 | 7022 | 0.220 |
Why?
|
Prevalence | 8 | 2021 | 14992 | 0.210 |
Why?
|
Angiotensins | 1 | 2022 | 145 | 0.210 |
Why?
|
Aminosalicylic Acid | 1 | 2021 | 23 | 0.210 |
Why?
|
Smoking | 2 | 2016 | 8879 | 0.210 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1574 | 0.210 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 1752 | 0.210 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5059 | 0.210 |
Why?
|
Thioglycolates | 1 | 2021 | 38 | 0.200 |
Why?
|
Cause of Death | 3 | 2021 | 3564 | 0.200 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 52 | 0.200 |
Why?
|
Urate Oxidase | 1 | 2021 | 35 | 0.200 |
Why?
|
Acute Chest Syndrome | 1 | 2020 | 30 | 0.200 |
Why?
|
Immunization Schedule | 1 | 2021 | 222 | 0.190 |
Why?
|
Medication Therapy Management | 1 | 2021 | 127 | 0.190 |
Why?
|
Glucosides | 1 | 2023 | 387 | 0.190 |
Why?
|
Prescriptions | 3 | 2021 | 360 | 0.180 |
Why?
|
Retrospective Studies | 16 | 2022 | 74206 | 0.180 |
Why?
|
Infant, Newborn | 13 | 2022 | 24985 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 2259 | 0.180 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 14974 | 0.170 |
Why?
|
Toluidines | 1 | 2019 | 19 | 0.170 |
Why?
|
Crotonates | 1 | 2019 | 19 | 0.170 |
Why?
|
Azathioprine | 2 | 2021 | 352 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2021 | 271 | 0.170 |
Why?
|
Multivariate Analysis | 4 | 2014 | 12249 | 0.170 |
Why?
|
Antidepressive Agents | 3 | 2017 | 2750 | 0.170 |
Why?
|
Lawyers | 1 | 2019 | 39 | 0.170 |
Why?
|
Hydroxybutyrates | 1 | 2019 | 84 | 0.170 |
Why?
|
Time Factors | 11 | 2022 | 40186 | 0.170 |
Why?
|
Sweden | 1 | 2021 | 1321 | 0.170 |
Why?
|
Spironolactone | 1 | 2022 | 377 | 0.170 |
Why?
|
Ondansetron | 1 | 2018 | 89 | 0.160 |
Why?
|
Therapeutic Equivalency | 1 | 2018 | 143 | 0.160 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 752 | 0.160 |
Why?
|
Sertraline | 1 | 2019 | 205 | 0.160 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 767 | 0.160 |
Why?
|
Medical Record Linkage | 1 | 2018 | 279 | 0.150 |
Why?
|
Antiemetics | 1 | 2018 | 174 | 0.150 |
Why?
|
Preoperative Period | 1 | 2019 | 548 | 0.150 |
Why?
|
Age Distribution | 2 | 2014 | 2918 | 0.150 |
Why?
|
Postoperative Complications | 1 | 2019 | 15019 | 0.150 |
Why?
|
Pyridones | 1 | 2021 | 690 | 0.150 |
Why?
|
Geography | 1 | 2019 | 686 | 0.150 |
Why?
|
Amphetamine | 1 | 2017 | 219 | 0.150 |
Why?
|
Penicillamine | 1 | 2016 | 59 | 0.140 |
Why?
|
Drug Repositioning | 1 | 2018 | 225 | 0.140 |
Why?
|
Algorithms | 2 | 2018 | 13765 | 0.140 |
Why?
|
Lung Diseases, Interstitial | 2 | 2021 | 776 | 0.140 |
Why?
|
Quality of Health Care | 1 | 2011 | 4342 | 0.140 |
Why?
|
Citalopram | 1 | 2019 | 391 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2019 | 378 | 0.140 |
Why?
|
Nausea | 1 | 2018 | 641 | 0.140 |
Why?
|
Investments | 1 | 2017 | 135 | 0.140 |
Why?
|
Serologic Tests | 1 | 2017 | 368 | 0.140 |
Why?
|
Hyperuricemia | 1 | 2018 | 211 | 0.130 |
Why?
|
Pre-Eclampsia | 3 | 2020 | 1150 | 0.130 |
Why?
|
Minocycline | 1 | 2016 | 162 | 0.130 |
Why?
|
Polyethylene Glycols | 1 | 2021 | 1179 | 0.130 |
Why?
|
Triazoles | 1 | 2021 | 909 | 0.130 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2015 | 80 | 0.130 |
Why?
|
Back Pain | 1 | 2019 | 539 | 0.130 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 5343 | 0.130 |
Why?
|
Bradycardia | 1 | 2016 | 290 | 0.130 |
Why?
|
Postpartum Hemorrhage | 1 | 2018 | 244 | 0.130 |
Why?
|
Clinical Coding | 1 | 2016 | 174 | 0.130 |
Why?
|
Influenza Vaccines | 1 | 2021 | 715 | 0.130 |
Why?
|
Codeine | 1 | 2014 | 47 | 0.130 |
Why?
|
Heart Defects, Congenital | 4 | 2018 | 4446 | 0.130 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14721 | 0.130 |
Why?
|
Hydrocodone | 1 | 2014 | 46 | 0.120 |
Why?
|
Hepatitis B virus | 1 | 2017 | 485 | 0.120 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2016 | 512 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 834 | 0.120 |
Why?
|
Cleft Lip | 1 | 2018 | 437 | 0.120 |
Why?
|
Infant | 4 | 2020 | 34337 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 940 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2019 | 1297 | 0.120 |
Why?
|
Methylphenidate | 1 | 2017 | 469 | 0.120 |
Why?
|
Self Report | 2 | 2016 | 3407 | 0.120 |
Why?
|
International Classification of Diseases | 1 | 2018 | 849 | 0.120 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 24031 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2260 | 0.110 |
Why?
|
Epidemiology | 1 | 2016 | 289 | 0.110 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 1335 | 0.110 |
Why?
|
Neuralgia | 1 | 2019 | 522 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 612 | 0.110 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 571 | 0.110 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13698 | 0.110 |
Why?
|
Psychotic Disorders | 2 | 2018 | 2934 | 0.110 |
Why?
|
Hepatitis B | 1 | 2017 | 660 | 0.110 |
Why?
|
Adenosine | 1 | 2017 | 806 | 0.110 |
Why?
|
Drug Industry | 1 | 2018 | 740 | 0.110 |
Why?
|
Premature Birth | 3 | 2020 | 1619 | 0.110 |
Why?
|
Age Factors | 3 | 2020 | 18339 | 0.110 |
Why?
|
Laxatives | 1 | 2012 | 81 | 0.110 |
Why?
|
Calcium Channel Blockers | 1 | 2015 | 684 | 0.110 |
Why?
|
Ticlopidine | 1 | 2017 | 885 | 0.100 |
Why?
|
Ophthalmic Solutions | 1 | 2012 | 309 | 0.100 |
Why?
|
Models, Structural | 1 | 2011 | 365 | 0.100 |
Why?
|
Pyrazoles | 1 | 2021 | 1926 | 0.100 |
Why?
|
Opiate Substitution Treatment | 1 | 2015 | 385 | 0.100 |
Why?
|
Information Storage and Retrieval | 1 | 2017 | 820 | 0.100 |
Why?
|
Bipolar Disorder | 2 | 2019 | 4862 | 0.100 |
Why?
|
Infant, Newborn, Diseases | 1 | 2016 | 561 | 0.100 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11529 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2018 | 2216 | 0.100 |
Why?
|
Mood Disorders | 1 | 2017 | 1081 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1214 | 0.100 |
Why?
|
Influenza, Human | 1 | 2021 | 1438 | 0.100 |
Why?
|
Calcinosis | 1 | 2019 | 1466 | 0.090 |
Why?
|
Child | 6 | 2022 | 75163 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2205 | 0.090 |
Why?
|
Health Services Research | 1 | 2018 | 1830 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3822 | 0.090 |
Why?
|
Fetal Diseases | 1 | 2015 | 884 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4938 | 0.090 |
Why?
|
Diuretics | 1 | 2012 | 572 | 0.090 |
Why?
|
Maternal Exposure | 1 | 2016 | 935 | 0.090 |
Why?
|
Central Nervous System | 1 | 2017 | 1301 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2016 | 835 | 0.090 |
Why?
|
Sex Distribution | 1 | 2014 | 2315 | 0.090 |
Why?
|
Double-Blind Method | 1 | 2023 | 11883 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1135 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12817 | 0.080 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 2860 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2324 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2019 | 1429 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2743 | 0.080 |
Why?
|
Child, Preschool | 2 | 2020 | 40440 | 0.080 |
Why?
|
Disease Progression | 2 | 2021 | 13157 | 0.080 |
Why?
|
Abruptio Placentae | 2 | 2019 | 117 | 0.080 |
Why?
|
Prognosis | 4 | 2022 | 28737 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5937 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3511 | 0.070 |
Why?
|
Arthritis | 1 | 2011 | 656 | 0.070 |
Why?
|
Dermatologic Agents | 2 | 2019 | 265 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2012 | 2429 | 0.070 |
Why?
|
Patient Readmission | 1 | 2019 | 3048 | 0.070 |
Why?
|
Risperidone | 2 | 2018 | 380 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2016 | 0.060 |
Why?
|
Fetal Growth Retardation | 2 | 2019 | 559 | 0.060 |
Why?
|
Bone Density | 1 | 2017 | 3433 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 1138 | 0.060 |
Why?
|
Antimanic Agents | 2 | 2019 | 505 | 0.060 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1053 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9669 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19624 | 0.060 |
Why?
|
Prospective Studies | 3 | 2017 | 51869 | 0.060 |
Why?
|
Pregnancy Trimester, Third | 2 | 2015 | 558 | 0.060 |
Why?
|
Seizures | 1 | 2015 | 2745 | 0.060 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 6197 | 0.060 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 3530 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 20941 | 0.050 |
Why?
|
Models, Statistical | 1 | 2017 | 5082 | 0.050 |
Why?
|
Gestational Age | 2 | 2022 | 3443 | 0.050 |
Why?
|
Health Surveys | 1 | 2011 | 4001 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3277 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4488 | 0.050 |
Why?
|
Chronic Disease | 2 | 2017 | 9022 | 0.050 |
Why?
|
Sex Factors | 1 | 2014 | 10382 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 2769 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2011 | 2695 | 0.050 |
Why?
|
France | 1 | 2021 | 509 | 0.050 |
Why?
|
Pharmacoepidemiology | 1 | 2022 | 322 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9245 | 0.040 |
Why?
|
Uricosuric Agents | 1 | 2018 | 27 | 0.040 |
Why?
|
Deductibles and Coinsurance | 1 | 2021 | 319 | 0.040 |
Why?
|
Hepatitis B Antigens | 1 | 2017 | 40 | 0.040 |
Why?
|
Isotretinoin | 1 | 2019 | 105 | 0.040 |
Why?
|
Pregnancy Outcome | 2 | 2019 | 2736 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 435 | 0.040 |
Why?
|
Carbamazepine | 1 | 2018 | 228 | 0.040 |
Why?
|
Mental Disorders | 1 | 2017 | 6436 | 0.040 |
Why?
|
Hepatitis B Antibodies | 1 | 2017 | 152 | 0.040 |
Why?
|
Thalidomide | 1 | 2022 | 871 | 0.040 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2022 | 1105 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 144 | 0.040 |
Why?
|
Labetalol | 1 | 2016 | 30 | 0.040 |
Why?
|
Pregnancy Trimesters | 1 | 2017 | 190 | 0.040 |
Why?
|
Taiwan | 1 | 2017 | 499 | 0.040 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2017 | 190 | 0.040 |
Why?
|
Atenolol | 1 | 2016 | 98 | 0.040 |
Why?
|
Metoprolol | 1 | 2016 | 90 | 0.040 |
Why?
|
Pharmaceutical Services | 1 | 2017 | 139 | 0.040 |
Why?
|
Treatment Failure | 1 | 2022 | 2614 | 0.030 |
Why?
|
Budgets | 1 | 2017 | 224 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 613 | 0.030 |
Why?
|
Triazines | 1 | 2017 | 307 | 0.030 |
Why?
|
Health Services | 1 | 2020 | 749 | 0.030 |
Why?
|
Patient Simulation | 1 | 2017 | 312 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2368 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 499 | 0.030 |
Why?
|
Policy | 1 | 2017 | 464 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2018 | 839 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 905 | 0.030 |
Why?
|
Virus Diseases | 1 | 2019 | 703 | 0.030 |
Why?
|
Pregnant Women | 1 | 2017 | 543 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2017 | 850 | 0.030 |
Why?
|
Ischemic Attack, Transient | 1 | 2018 | 914 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1647 | 0.030 |
Why?
|
Government Regulation | 1 | 2016 | 521 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2017 | 2387 | 0.020 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2016 | 455 | 0.020 |
Why?
|
DNA, Viral | 1 | 2017 | 2270 | 0.020 |
Why?
|
Thiazoles | 1 | 2018 | 1488 | 0.020 |
Why?
|
Causality | 1 | 2017 | 1235 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2019 | 1400 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1193 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 679 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2022 | 9789 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2022 | 3388 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2017 | 1126 | 0.020 |
Why?
|
Poverty | 1 | 2020 | 2581 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1389 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9839 | 0.020 |
Why?
|
Income | 1 | 2017 | 1829 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3621 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2481 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4200 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1787 | 0.020 |
Why?
|
Hepatitis C | 1 | 2016 | 1565 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 2001 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 2954 | 0.020 |
Why?
|
Phenotype | 1 | 2022 | 16272 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2016 | 2114 | 0.020 |
Why?
|
Inpatients | 1 | 2016 | 2395 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2022 | 18033 | 0.010 |
Why?
|
Epilepsy | 1 | 2017 | 3153 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3059 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4079 | 0.010 |
Why?
|
Asthma | 1 | 2019 | 5838 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2016 | 4187 | 0.010 |
Why?
|
Depression | 1 | 2016 | 7454 | 0.010 |
Why?
|
Mice | 1 | 2022 | 80300 | 0.010 |
Why?
|
Animals | 1 | 2022 | 168714 | 0.010 |
Why?
|
HIV Infections | 1 | 2016 | 16202 | 0.010 |
Why?
|